Newsletter | December 22, 2020

12.22.20 -- Biosimilar Development Top 10 Of 2020


As we near the close of another eventful year, it’s worthwhile to reflect upon the major challenges, trends, and learnings that emerged in the biosimilar industry over the past year. This Top 10 Newsletter showcases the most popular articles published in Biosimilar Development in 2020. As this lineup of articles reveals, 2020 was a big year for biosimilars, despite the complexities posed by the COVID-19 pandemic. We saw great leaps in market competition, particularly in the U.S. market, growing support from sites of care, patients, and physicians, and the rise of small-to-midsize companies tackling biosimilar pipeline development. As is to be expected in a growing market, however, questions and concerns remain about proposed or existing policies, continued barriers to market access, and regulatory pathway inefficiencies.

I hope you find this year-end review both thought-provoking and beneficial — and that you have a wonderful holiday season. If you have any ideas for future editorial coverage or are interested in submitting your own content, please email me. I would love to hear from you.

Thank you, as always, for your continued readership and participation in this crucial industry!

Anna Rose Welch, Chief Editor

Top 10 From The Editor
Top 10 Featured Editorial
  1. Which Biosimilar Companies Will Thrive In 2025?
  2. Biosimilar Pipeline Experiencing 12% Annual Growth: A Progress Update
  3. The Case For Optimism In The U.S. Biosimilar Market
  4. Weighing The Potential Of Humira Biosimilars In The U.S.
  5. An Update On 2020 U.S. Biosimilars Regulation And Litigation
  6. End Of The Enbrel Battle: How Amgen Beat Sandoz
  7. Biosimilars: The New World Of Commercialization
Top 10 Industry Insights
  1. Protein Thermal Shift Assays Made Easy
    Bio-Rad Laboratories, Inc.